Home » Newsletters » BioWorld Science

BioWorld Science

April 22, 2010

View Archived Issues

Medvir discovers novel selective cathepsin K inhibitors

Boehringer Ingelheim claims new inhibitors of microsomal prostaglandin E synthase 1

Italian scientists claim new agents with antimalarial activity

NeuroSearch discloses new potassium channel modulators

Gilead discloses clinical data on HCV NS3 protease inhibitor GS-9256

Characterization of filibuvir resistance in HCV patients when coadministered with PEG-INF/RBV

Dual PI3K-alpha/mTOR inhibitors discovered by Pfizer

Preclinical and phase I data presented on antimicrobial pleuromutilin BC-3781

Cheminpharma presents preclinical data on new MEK 1 inhibitor

Pfizer describes new oxazolidinone antibacterial

Hospira enters definitive merger agreement to acquire Javelin

EMA recommends Cell Therapeutics submit revised PIP for pixantrone

Swedish Orphan Biovitrum's Kiobrina improves preterm infant growth speed in phase II trial

Novel photosensitizer porphyrins discovered at CeramOptec

Silence Therapeutics and AstraZeneca extend siRNA delivery collaboration

FDA approves Stemedica's IND to evaluate stem cells in ischemic stroke patients

Dutogliptin reduces HbA1c in phase III trial in type 2 diabetes

Alexion reaches enrollment goals in Solaris trials in atypical hemolytic uremic syndrome

EMA's COMP notifies CytRX of positive opinion on bafetinib in CML

NeoPharm starts enrollment in phase II LE-DT trial in pancreatic cancer

Genentech and Seattle Genetics to renew antibody-drug conjugate collaboration

DBM receives NIH grant to continue developing anti-inflammatory phytochemicals

NanoBio and University of Michigan launch program for therapeutic intranasal HBV vaccine

FDA approves Zortress to prevent kidney transplant rejection in adults

Biotie maintains global rights to BTT-1023 for inflammatory diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...